The BioInsights Podcast

0

The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.

Recent Episodes
  • Enhancing mRNA results through strategic RNA design and quality control
    Mar 27, 2025 – 12:53
  • For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications
    Mar 13, 2025 – 19:09
  • Exploring challenges, opportunities and state-of-the-art tools in the lipid nanoparticle space
    Feb 19, 2025 – 15:03
  • Driving innovation in cell and gene therapy: the role of AI and robotics
    Jan 27, 2025 – 15:38
  • Spatial mapping: shaping the future of I-O diagnostics and treatment
    Dec 6, 2024 – 38:44
  • Pioneering quality control in biomanufacturing of cell and gene therapies
    Dec 5, 2024 – 28:08
  • Preparing for tomorrow’s cell and gene therapies today: lessons from 30 years in the field
    Sep 6, 2024 – 25:36
  • Insights into advanced therapies in the context of evolving funding and M&A environments
    Jun 14, 2024 – 22:37
  • Fit for function: developing potency assays reflective of the in vivo environment
    May 10, 2024 – 28:20
  • Gene therapy is having a monumental year: how can the industry keep up with supply?
    Apr 4, 2024 – 23:36
  • A deep dive in to generative AI applications in I-O
    Mar 18, 2024 – 43:52
  • Developing novel radioimmunotherapy combinations for lung cancer treatment
    Mar 12, 2024 – 14:57
  • Focusing on the fundamentals: what do and don’t we know about mRNA delivery?
    Mar 11, 2024 – 45:24
  • Navigating genomics and transcriptomics in the immuno-oncology space
    Mar 1, 2024 – 20:23
  • Avian influenza and the risk of pandemic
    Feb 27, 2024 – 23:38
  • Exploring the landscape of novel targets & pathways in immuno-oncology
    Dec 4, 2023 – 17:05
  • Multiomics integration: advancing pediatric cancer immunotherapy
    Nov 2, 2023 – 19:37
  • Building with the patient in mind: designing a state-of-the-art facility for viral vector manufacturing
    Oct 10, 2023 – 28:44
  • Can AAV continue to deliver the promise of gene therapy?
    Sep 13, 2023 – 21:37
  • Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)
    Aug 30, 2023 – 20:04
  • Investing long-term in the cell & gene therapies of the future
    Aug 22, 2023 – 15:25
  • Happy medium: considerations in scaling cell culture media strategies
    Aug 16, 2023 – 19:11
  • Applying multiomics to novel target discovery in immuno-oncology
    Aug 8, 2023 – 18:42
  • Modernizing cell therapy manufacturing to reduce vein-to-vein times
    Jul 26, 2023 – 23:49
  • Inducing innate immune responses with particulate adjuvants
    Jul 26, 2023 – 13:38
  • Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development
    Jun 9, 2023 – 31:06
  • Non-viral methods for ex vivo cell & gene therapy: is the future non-viral?
    May 31, 2023 – 21:37
  • Solving challenges in cell therapy clinical trials & effectively delivering complex studies in advanced therapeutics
    Apr 17, 2023 – 25:00
  • Shear ignorance? Think again: breaking the perception of shear within viral vector manufacturing
    Apr 6, 2023 – 18:05
  • Challenges in cryogenic storage containers for cell and gene therapy
    Mar 22, 2023 – 17:48
  • Maximizing Efficiency and Flexibility in Viral Vector Manufacturing Scale-up
    Mar 2, 2023 – 37:09
  • Improvement of viral vector purification using Mustang Q membrane chromatography
    Dec 13, 2022 – 32:25
  • Shear ignorance? Think again: breaking the perception of shear within viral vector manufacturing
    Nov 9, 2022 – 18:05
  • CAR-T cells: from cancer to autoimmunity
    Oct 12, 2022 – 30:02
  • Tales, tips & teachable moments from applications support veterans
    Oct 11, 2022 – 25:21
  • Access to vaccines: how can we leverage technology innovations to achieve greater vaccine equity?
    Sep 30, 2022 – 18:36
  • De-risk & accelerate the drug development process for gene therapy
    Sep 29, 2022 – 11:31
  • Working Together to Safely Advance Cell & Gene Therapies
    Sep 27, 2022 – 01:00:00
  • Learning from pediatric CAR-T development: insights from manufacturing unique patient doses
    Sep 26, 2022 – 20:55
  • Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take us
    Sep 12, 2022 – 28:11
  • Making the switch from autologous to allogeneic cell therapy
    Sep 9, 2022 – 27:55
  • Accelerating cures: funding stem cell innovation & ideas in an evolving cell therapy space
    Sep 5, 2022 – 15:52
  • Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take us
    Aug 16, 2022 – 28:11
  • Achieving better AAV vector productivity and product quality
    Aug 5, 2022 – 18:59
  • Partnering in life sciences: what is the ‘secret sauce’ for success? PART 2
    Jul 25, 2022 – 19:33
  • Partnering in life sciences: what is the secret sauce for success? PART 1: The Big Pharma perspective
    Jul 18, 2022 – 28:33
  • Where will tomorrow’s workforce come from? PART 4: Who are tomorrow’s cell and gene therapy workers?
    Jun 20, 2022 – 44:59
  • Where will tomorrow’s workforce come from? PART 3: Innovation in staff sourcing, training and retention - what works and what doesn’t?
    Jun 20, 2022 – 26:01
  • Where will tomorrow’s workforce come from? PART 2: How is the educational system responding, and how can the cell and gene therapy community at large help?
    Jun 7, 2022 – 32:30
  • Where will tomorrow’s workforce come from? PART1: Framing the issue
    Jun 7, 2022 – 28:45
Recent Reviews
Similar Podcasts
Disclaimer: The podcast and artwork on this page are property of the podcast owner, and not endorsed by UP.audio.